XLO

Xilio Therapeutics, Inc. NASDAQ Listed Oct 22, 2021

Healthcare ·Biotechnology ·US · xiliotx.com

$9.05

+1.80% vs $8.89

Mkt Cap $756.5M

52w Low $7.14 38.7% of range 52w High $12.08

50d MA $8.28 200d MA $9.17

P/E (TTM) —

EV/EBITDA —

P/B 21.4x

Debt/Equity 0.2x

ROE -99.3%

P/FCF -137.3x

RSI (14) 85.70

ATR (14) $0.49

Beta -0.12

50d MA $8.28

200d MA $9.17

Avg Volume 53.8K

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

SIC Code

2834

CIK (SEC)

1840233

Phone

617 430 4680

828 Winter Street · Waltham, MA 02451 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 23, 2026	AMC	-1.68	-0.85	+49.4%	7.86	-0.8%	+6.5%	+1.9%	+1.8%	-4.1%	-1.0%	—
Nov 13, 2025	AMC	-0.45	-0.03	+93.3%	9.82	-5.9%	+0.8%	+2.4%	+3.6%	+7.6%	-7.1%	—
Aug 14, 2025	AMC	-1.10	-0.16	+85.5%	9.84	+1.0%	+0.9%	-0.3%	-3.6%	-2.6%	+1.0%	—
May 8, 2025	AMC	-2.70	-0.18	+93.3%	10.08	-1.4%	-1.4%	+2.9%	+57.4%	-26.1%	-5.9%	—
Mar 11, 2025	AMC	-3.03	-0.20	+93.4%	11.10	-0.4%	+4.1%	-3.1%	+0.1%	+0.9%	-4.0%	—
Nov 7, 2024	AMC	-0.25	-0.22	+12.0%	14.56	-4.8%	-4.8%	+10.1%	-0.9%	-7.6%	-4.1%	—
Aug 8, 2024	AMC	-0.23	-0.24	-4.3%	12.03	+0.7%	+0.9%	-3.8%	-4.7%	+3.8%	+0.6%	—
May 14, 2024	AMC	-0.11	-0.62	-463.6%	15.26	+0.0%	+2.8%	-3.6%	+5.6%	+9.6%	-4.0%	—
Apr 1, 2024	AMC	-0.64	-0.64	+0.0%	21.42	-7.2%	-3.3%	-12.2%	-6.9%	-0.8%	+22.5%	—
Nov 9, 2023	AMC	-0.81	-0.61	+24.7%	22.40	+9.4%	-10.6%	-1.4%	-7.1%	+2.3%	-2.6%	—
Aug 14, 2023	AMC	-0.87	-0.70	+19.5%	40.04	-3.5%	+0.3%	-3.0%	-3.4%	-2.6%	+5.7%	—
May 9, 2023	AMC	-0.89	-0.83	+6.7%	44.80	-3.1%	+0.0%	+0.0%	-0.9%	-3.2%	+2.3%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Nov 8	Raymond James	Maintains	Outperform → Outperform	—	$14.56	$13.86	-4.8%	-4.8%	+10.1%	-0.9%	-7.6%	-4.1%
May 30	Chardan Capital	Maintains	Buy → Buy	—	$42.84	$45.50	+6.2%	-0.3%	+0.0%	-4.6%	+2.4%	+3.5%
Jan 27	Morgan Stanley	Maintains	Overweight → Overweight	—	$57.82	$56.00	-3.1%	+3.6%	-7.2%	-8.1%	+1.4%	+0.8%
Nov 10	Raymond James	Maintains	Outperform → Outperform	—	$32.06	$32.06	+0.0%	+6.6%	+2.3%	-1.4%	-2.4%	+9.2%
Aug 10	Morgan Stanley	Maintains	Overweight → Overweight	—	$33.88	$33.04	-2.5%	+2.1%	+2.0%	-2.4%	-0.4%	-0.4%

Institutional (13F) — Top 10 All ↗

#	Manager	Shares	Value	Chg	Period
1	Vanguard Capital Management Llc	123,660	$1M	New	Mar 2026
2	Stonepine Capital Management, Llc	64,162	$540K	New	Mar 2026
3	Renaissance Technologies Llc	49,566	$417K	New	Mar 2026
4	Aju Ib Investment Co., Ltd.	47,695	$401K	New	Mar 2026
5	Fmr Llc	36,558	$307K	New	Mar 2026
6	Velan Capital Investment Management Lp	14,285	$120K	New	Mar 2026
7	Cwm, Llc	4,206	$35K	New	Mar 2026
8	Ubs Group Ag	4,038	$34K	New	Mar 2026
9	Jpmorgan Chase & Co	240	$2K	New	Mar 2026
10	Royal Bank Of Canada	91	$1K	New	Mar 2026

Mutual Funds / ETFs (N-PORT) — Top 1 All ↗

#	Fund	Shares	Value	Period
1	Guggenheim Active Allocation Fund	43	$23	Feb 2026

Data updated apr 27, 2026 10:35am · Source: financialmodelingprep.com